Amgen kept neutral by Merrill

Merrill Lynch analyst Eric Ende maintained Amgen Inc. at neutral after the International Trade Commission ruled that Roche's activities related to pegylated erythropoietin (Peg-EPO) in the United States do not constitute patent infringement. The activities are related to Roche's efforts to obtain Food and Drug Administration approval of CERA. Patent litigation in the District Court of Massachusetts continues to overhang the stock. Shares of the Thousand Oaks, Calif.-based biotechnology company were up 21 cents, or 0.32%, at $66.60 on volume of 5,098,029 shares versus the three-month running average of 8,989,280 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.